CareDx (NASDAQ: CDNA) reported a 39% year-over-year revenue growth for Q1, bringing in $447 million to $465 million in expected full-year revenue. The company serves over 200 solid organ transplant programs in the U.S. and has performed over 1 million molecular tests for organ rejection. With a cash position of approximately $189 million and no debt, CareDx aims for adjusted EBITDA between $43 million and $57 million.
During the Jefferies Healthcare Conference, CEO John Hanna emphasized the company’s strategic focus on transplant diagnostics and specialty oncology. The recent acquisition of Naveris enhances CareDx’s oncology portfolio, with Naveris expected to grow 30% to 40% annually over the next three years. Key segments include Testing Services, which saw a 48% increase, while Lab Products declined by 4% due to earlier stocking orders.
Looking ahead, CareDx’s pipeline includes AlloHeme for hematologic oncology and AlloSure Liver for organ transplant monitoring. The company aims to publish a manuscript from the ACROBAT trial by 2026, signaling significant research advancements in its offerings.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
